Merck's LIPFENDRA (enlicitide), the first FDA-approved oral PCSK9 inhibitor, approved 16 July 2026 at a list price of $315 for a 30-day supply. Amgen's Repatha (evolocumab) is already available for ...
A bright clinical concept image showing the stabilizer ceiling in amyloidosis, where modern background therapy reduces the detectable benefit of add-on drugs. HELIOS-B cleared its endpoint.
Pharma business news, market intelligence, and CEO-level case studies.
Oral PCSK9 Inhibitor Approved: LIPFENDRA Price vs Repatha Witfire Elite Cardiometabolic Pricing & Access Market Case Studies Long Read Pharma Market Case Studies Witfire Elite View Oral PCSK9… ...
Oral PCSK9 Inhibitor Approved: LIPFENDRA Price vs Repatha Witfire Elite Cardiometabolic Pricing & Access Market Case Studies Long Read Pharma Market Case Studies Witfire Elite View Oral PCSK9… ...
Oral PCSK9 Inhibitor Approved: LIPFENDRA Price vs Repatha Witfire Elite Cardiometabolic Pricing & Access Market Case Studies Long Read Pharma Market Case Studies Witfire Elite View Oral PCSK9… ...
Oral PCSK9 Inhibitor Approved: LIPFENDRA Price vs Repatha Witfire Elite Cardiometabolic Pricing & Access Market Case Studies Long Read Pharma Market Case Studies Witfire Elite View Oral PCSK9… ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results